

Table 4.26

Cancer of the Female Breast(In Situ)

Percent Distribution and Counts by Histology among Histologically Confirmed Cases, 2013-2017
Females by Race

Histology ^a	All Races		White		Black		Asian/Pacific Islander		American Indian/ Alaska Native ^b		Hispanic ^c	
	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent	Count	Percent
Adenocarcinoma ^d	112,659	99.9%	85,269	99.9%	13,833	99.9%	11,385	99.9%	346	99.7%	12,906	99.9%
Adenocarcinoma <i>in situ</i> , NOS (8140/2)	-	-	-	-	-	-	-	-	-	-	-	-
Ductal carcinoma <i>in situ</i> ^e	91,842	81.5%	68,384	80.1%	11,814	85.3%	9,993	87.7%	305	87.9%	10,610	82.1%
Cribriform carcinoma <i>in situ</i> (8201/2)	10,106	9.0%	7,450	8.7%	1,300	9.4%	1,171	10.3%	24	6.9%	1,139	8.8%
Ductal carcinoma <i>in situ</i> , solid type(8230/2)	8,130	7.2%	6,253	7.3%	890	6.4%	866	7.6%	28	8.1%	791	6.1%
Ductal carcinoma <i>in situ</i> , NOS (8500/2)	24,909	22.1%	18,910	22.2%	3,041	22.0%	2,411	21.2%	101	29.1%	2,864	22.2%
Comedocarcinoma <i>in situ</i> (8501/2)	8,251	7.3%	6,249	7.3%	943	6.8%	930	8.2%	31	8.9%	907	7.0%
Ductal carcinoma <i>in situ</i> papillary(8503/2)	1,650	1.5%	1,072	1.3%	342	2.5%	196	1.7%	-	-	221	1.7%
Noninfiltrating intracystic carcinoma(8504/2)	362	0.3%	231	0.3%	59	0.4%	64	0.6%	-	-	37	0.3%
Ductal carcinoma <i>in situ</i> micropapillary(8507/2)	1,502	1.3%	1,146	1.3%	211	1.5%	122	1.1%	-	-	170	1.3%
Intraductal with other types of carcinoma <i>in situ</i> (8523/2)	36,670	32.5%	26,882	31.5%	5,007	36.2%	4,187	36.7%	112	32.3%	4,457	34.5%
Lobular carcinoma <i>in situ</i> (8520/2-8521/2, 8524/2)	16,631	14.7%	13,576	15.9%	1,549	11.2%	1,042	9.1%	33	9.5%	1,840	14.2%
Lobular carcinoma <i>in situ</i> , NOS (8520/2)	16,617	14.7%	13,569	15.9%	1,543	11.1%	1,041	9.1%	33	9.5%	1,839	14.2%
Lobular CIS ^f with other CIS ^f (8524/2)	-	-	-	-	-	-	-	-	-	-	-	-
Intraductal and lobular <i>in situ</i> carcinoma (8522/2)	3,519	3.1%	2,822	3.3%	387	2.8%	266	2.3%	-	-	373	2.9%
Other adenocarcinomas ^g	661	0.6%	483	0.6%	82	0.6%	83	0.7%	-	-	83	0.6%
Other <i>in situ</i> histologies ^h	98	0.1%	66	0.1%	-	-	-	-	-	-	-	-
Total	112,757	100.0%	85,335	100.0%	13,847	100.0%	11,396	100.0%	347	100.0%	12,917	100.0%

Source: SEER 21 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, Georgia excluding ATL/RG, Idaho, New York and Massachusetts).

Percents may not sum to 100 due to rounding.

^a Excludes Kaposi Sarcoma, mesothelioma, lymphomas, leukemias, myelomas, lymphoreticular, and immunoproliferative diseases.

^b Estimates for American Indian/Alaska Native are based on the Purchased/Referred Care Delivery Area (PRCDA) counties.

^c Hispanic is not mutually exclusive from whites, blacks, Asian/Pacific Islanders, and American Indians/Alaska Natives.

^d Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

^e Adenocarcinoma includes histologies 8050,8140-8147,8160-8162,8180-8221,8230,8250-8507,8514,8520-8551,8560,8570-8574,8576,8940-8941.

^f Ductal carcinoma includes histologies 8201, 8230, 8401, 8500-8507, 8523.

^g CIS = Carcinoma *in situ*.

^h Other adenocarcinomas include 8050, 8141-8147, 8160-8162, 8180-8200, 8202-8221, 8250-8400, 8402-8499, 8514, 8525-8551, 8560, 8570-8574, 8576, 8940-8941.

ⁱ Other histologies include 8000-8049, 8051-8139, 8148-8159, 8163-8179, 8222-8229, 8231-8249, 8508-8513, 8515-8519, 8552-8559, 8561-8569, 8575, 8577-8939, 8942-9989.

- Statistic not shown due to fewer than 16 cases during the time period.